SXI Life Sciences
6.851,92
PKT
-17,54
PKT
-0,26
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
23.12.22 | Roche Overweight | Barclays Capital | |
14.12.22 | Novartis Neutral | UBS AG | |
14.12.22 | Roche Neutral | UBS AG | |
12.12.22 | Novartis Buy | Jefferies & Company Inc. | |
09.12.22 | Novartis Sell | Deutsche Bank AG | |
08.12.22 | Novartis Market-Perform | Bernstein Research | |
08.12.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
07.12.22 | Novartis Sell | Deutsche Bank AG | |
06.12.22 | Novartis Neutral | UBS AG | |
02.12.22 | Roche Hold | Deutsche Bank AG | |
22.11.22 | Novartis Sell | Deutsche Bank AG | |
15.11.22 | Roche Hold | Deutsche Bank AG | |
14.11.22 | Roche Outperform | Credit Suisse Group | |
14.11.22 | Roche Neutral | JP Morgan Chase & Co. | |
14.11.22 | Roche Overweight | Barclays Capital | |
14.11.22 | Roche Buy | Jefferies & Company Inc. | |
14.11.22 | Roche Neutral | UBS AG | |
14.11.22 | Roche Outperform | Bernstein Research | |
01.11.22 | Roche Hold | Deutsche Bank AG | |
27.10.22 | Novartis Sell | Deutsche Bank AG | |
26.10.22 | Novartis Market-Perform | Bernstein Research | |
26.10.22 | Novartis Underperform | Credit Suisse Group | |
26.10.22 | Novartis Underweight | JP Morgan Chase & Co. | |
26.10.22 | Novartis Underweight | Barclays Capital | |
25.10.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
25.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
25.10.22 | Novartis Sell | Deutsche Bank AG | |
25.10.22 | Novartis Neutral | UBS AG | |
25.10.22 | Novartis Buy | Jefferies & Company Inc. | |
24.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
21.10.22 | BB Biotech Add | Baader Bank | |
21.10.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
19.10.22 | Roche Neutral | JP Morgan Chase & Co. | |
19.10.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
19.10.22 | Roche Hold | Deutsche Bank AG | |
19.10.22 | Roche Outperform | Credit Suisse Group | |
19.10.22 | Roche Overweight | Barclays Capital | |
18.10.22 | Roche Neutral | UBS AG | |
18.10.22 | Roche Buy | Jefferies & Company Inc. | |
18.10.22 | Roche Outperform | Bernstein Research |